Form 8-K - Current report:
SEC Accession No. 0001193125-25-032092
Filing Date
2025-02-21
Accepted
2025-02-21 17:12:21
Documents
17
Period of Report
2025-02-18
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d934231d8k.htm   iXBRL 8-K 27413
2 EX-3.1 d934231dex31.htm EX-3.1 22427
6 GRAPHIC g934231g09j13.jpg GRAPHIC 1269
7 GRAPHIC g934231g76q23.jpg GRAPHIC 1841
8 GRAPHIC g934231g90u34.jpg GRAPHIC 3273
  Complete submission text file 0001193125-25-032092.txt   197391

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apto-20250218.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250218_lab.xml EX-101.LAB 20213
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250218_pre.xml EX-101.PRE 12608
20 EXTRACTED XBRL INSTANCE DOCUMENT d934231d8k_htm.xml XML 4181
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 25653104
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)